{
    "2019-01-30": [
        [
            {
                "time": "2019-01-30",
                "original_text": "Roche Halts Two Late-Stage Studies on Alzheimer's Candidate",
                "features": {
                    "keywords": [
                        "Roche",
                        "Alzheimer's",
                        "halted",
                        "studies"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2019-01-30",
                "original_text": "Johnson & Johnson Forecasts Modest EPS Growth for Fiscal 2019",
                "features": {
                    "keywords": [
                        "Johnson & Johnson",
                        "EPS",
                        "growth",
                        "forecast"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-01-30",
                "original_text": "Yacktman Fund's 4th Quarter Shareholder Commentary",
                "features": {
                    "keywords": [
                        "Yacktman",
                        "fund",
                        "shareholder",
                        "commentary"
                    ],
                    "sentiment_score": 0.0,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "general"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2019-01-30",
                "original_text": "What Are Johnson & Johnsonâ€™s Revenue Forecasts for Fiscal 2019?",
                "features": {
                    "keywords": [
                        "Johnson & Johnson",
                        "revenue",
                        "forecasts"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-01-30",
                "original_text": "What Analysts Recommend for Johnson & Johnson after Q4 Results",
                "features": {
                    "keywords": [
                        "analysts",
                        "recommendations",
                        "Q4",
                        "results"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-01-30",
                "original_text": "3 Big Pharmas Expecting a Softer 2019",
                "features": {
                    "keywords": [
                        "pharmas",
                        "softer",
                        "expectations"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2019-01-30",
                "original_text": "Health Care Sector Update for 01/30/2019: CODX, ANTM, ACIU, JNJ, PFE, MRK, ABT, AMGN",
                "features": {
                    "keywords": [
                        "healthcare",
                        "sector",
                        "update",
                        "stocks"
                    ],
                    "sentiment_score": 0.0,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-01-31",
                "original_text": "Pfizer, Inc. (PFE) Ex-Dividend Date Scheduled for January 31, 2019",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "ex-dividend",
                        "date"
                    ],
                    "sentiment_score": 0.3,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-01-30",
                "original_text": "Better Buy: Johnson & Johnson vs. Pfizer",
                "features": {
                    "keywords": [
                        "better buy",
                        "comparison",
                        "JNJ",
                        "PFE"
                    ],
                    "sentiment_score": 0.2,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}